Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in two upcoming investor conferences.
The company will participate in the TD Cowen 45th Annual Health Care Conference, where CEO Marino Garcia will conduct a fireside chat on March 5, 2025, at 11:50 a.m. ET in Boston. The presentation will be available via webcast on the company's website under the Investors section.
Additionally, Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025, in Miami.
Dianthus Therapeutics (Nasdaq: DNTH), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie anticorpali complementari di nuova generazione per gravi malattie autoimmuni, ha annunciato la sua partecipazione a due prossime conferenze per investitori.
L'azienda parteciperà alla 45ª Conferenza Annuale sulla Salute di TD Cowen, dove il CEO Marino Garcia condurrà una chiacchierata informale il 5 marzo 2025, alle 11:50 ET a Boston. La presentazione sarà disponibile tramite webcast sul sito web dell'azienda nella sezione Investitori.
Inoltre, Ryan Savitz, Direttore Finanziario e Direttore Commerciale, ospiterà incontri individuali con gli investitori al Jefferies Biotech on the Bay Summit il 12 marzo 2025, a Miami.
Dianthus Therapeutics (Nasdaq: DNTH), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias complementarias con anticuerpos de próxima generación para enfermedades autoinmunes severas, ha anunciado su participación en dos próximas conferencias para inversores.
La empresa participará en la 45ª Conferencia Anual de Salud de TD Cowen, donde el CEO Marino Garcia realizará una charla informal el 5 de marzo de 2025, a las 11:50 a.m. ET en Boston. La presentación estará disponible a través de un webcast en el sitio web de la empresa en la sección de Inversores.
Además, Ryan Savitz, Director Financiero y Director de Negocios, llevará a cabo reuniones individuales con inversores en el Jefferies Biotech on the Bay Summit el 12 de marzo de 2025, en Miami.
다이앤서스 테라퓨틱스(Dianthus Therapeutics) (Nasdaq: DNTH)는 중증 자가면역 질환을 위한 차세대 항체 보완 치료제를 개발하는 임상 단계의 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 TD Cowen 제45회 연례 건강관리 회의에 참여하며, CEO 마리노 가르시아가 2025년 3월 5일 오전 11시 50분 ET에 보스턴에서 파이어사이드 채팅을 진행할 예정입니다. 발표 내용은 회사 웹사이트의 투자자 섹션을 통해 웹캐스트로 제공됩니다.
또한, 라이언 사비츠, 최고재무책임자(CFO) 겸 최고사업책임자(CBO)가 2025년 3월 12일 마이애미에서 열리는 제프리 바이오텍 온 더 베이 서밋에서 1:1 투자자 회의를 주최할 예정입니다.
Dianthus Therapeutics (Nasdaq: DNTH), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies par anticorps complémentaires de nouvelle génération pour des maladies auto-immunes sévères, a annoncé sa participation à deux prochaines conférences pour investisseurs.
L'entreprise participera à la 45e Conférence Annuelle sur la Santé de TD Cowen, où le PDG Marino Garcia animera une discussion informelle le 5 mars 2025, à 11h50 ET à Boston. La présentation sera accessible par webcast sur le site web de l'entreprise dans la section Investisseurs.
De plus, Ryan Savitz, Directeur Financier et Directeur des Affaires, organisera des réunions individuelles avec les investisseurs lors du Jefferies Biotech on the Bay Summit le 12 mars 2025, à Miami.
Dianthus Therapeutics (Nasdaq: DNTH), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-Komplementtherapeutika der nächsten Generation für schwere Autoimmunerkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird an der 45. jährlichen Gesundheitskonferenz von TD Cowen teilnehmen, wo CEO Marino Garcia am 5. März 2025 um 11:50 Uhr ET in Boston ein informelles Gespräch führen wird. Die Präsentation wird über einen Webcast auf der Unternehmenswebsite im Bereich Investoren verfügbar sein.
Zusätzlich wird Ryan Savitz, Chief Financial Officer und Chief Business Officer, am 12. März 2025 in Miami Einzelgespräche mit Investoren beim Jefferies Biotech on the Bay Summit leiten.
- None.
- None.
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the following investor conferences:
- TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.m. ET and host one-on-one meetings with investors in Boston. A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
- Jefferies Biotech on the Bay Summit – Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings on Wednesday, March 12 in Miami
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
When is Dianthus Therapeutics (DNTH) presenting at the TD Cowen Healthcare Conference 2025?
Where can investors watch the DNTH TD Cowen conference presentation?
Which executives from DNTH are participating in the March 2025 investor conferences?
What type of therapeutic products is DNTH developing?
When and where is DNTH participating in the Jefferies Biotech on the Bay Summit?
